Form 4: Director Cini Disposes SONN Shares Post-Merger

Director John K. Cini disposed of all his Sonnet BioTherapeutics Holdings, Inc. common stock following the company's merger into Hyperliquid Strategies Inc.

Summary

• John K. Cini, a director of Sonnet BioTherapeutics Holdings, Inc. (SONN), reported a change in beneficial ownership.
• On December 2, 2025, Cini disposed of 14,116 shares of SONN Common Stock.
• This transaction occurred pursuant to a Business Combination Agreement (BCA) dated July 11, 2025.
• Under the BCA, Sonnet BioTherapeutics Holdings, Inc. merged with and into Hyperliquid Strategies Inc. (HSI), becoming a direct wholly-owned subsidiary of HSI.
• The disposed shares included 12,000 restricted stock units granted on July 11, 2025, which vested at the merger's effective time, and 2,116 previously vested restricted stock units.
• Each restricted stock unit was exchanged for one-fifth of a share of HSI Common Stock and one Contingent Value Right (CVR).
• Following the transaction, Cini's beneficial ownership in SONN is 0 shares.
• All reported amounts reflect a 1:22 reverse stock split effective August 31, 2023, and a 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 5

Explanation: This Form 4 filing is a neutral, factual report detailing a director's disposition of shares following a completed merger where Sonnet BioTherapeutics Holdings, Inc. became a wholly-owned subsidiary of Hyperliquid Strategies Inc. It reflects a structural change rather than operational performance or future guidance.

Positives

• The completion of the Business Combination Agreement indicates a strategic transaction has been finalized.
• The exchange of restricted stock units for HSI Common Stock and Contingent Value Rights (CVRs) provides former SONN RSU holders with an interest in the acquiring entity and potential future value.

Negatives

• Sonnet BioTherapeutics Holdings, Inc. ceased to exist as an independent public entity, becoming a wholly-owned subsidiary of HSI.
• The reporting person, a director of SONN, no longer holds any beneficial ownership in SONN, indicating a complete change in the company's structure.

Future Outlook

NA

Industry Context

This filing indicates a consolidation event within the biotechnology or pharmaceutical sector, where Sonnet BioTherapeutics, a company that had undergone significant reverse stock splits (often indicative of financial distress or efforts to maintain listing compliance), has been acquired by Hyperliquid Strategies Inc. This reflects a trend of larger or more stable entities acquiring smaller, potentially struggling, or strategically aligned companies to expand portfolios or consolidate market positions.

Comparison to Industry Standards

• Mergers and acquisitions are common in the biotech industry, especially for smaller companies like Sonnet BioTherapeutics (SONN) which had experienced multiple reverse stock splits (1:22 and 1:8), often signaling challenges in maintaining stock price or market capitalization.
• The use of Contingent Value Rights (CVRs) in the exchange for restricted stock units is a common mechanism in biotech mergers, allowing for potential future payouts tied to specific milestones (e.g., clinical trial success, regulatory approval) of the acquired assets, aligning interests between the acquirer and former equity holders of the target.
• The complete disposition of shares by a director post-merger is standard practice as the company ceases to be an independent entity and its shares are exchanged for those of the acquiring company or other consideration.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (former SONN): Their shares were exchanged for HSI Common Stock and CVRs, fundamentally changing their investment.
• Employees (former SONN): The merger likely impacts employment terms, reporting structures, and potentially job security as the company integrates into HSI.
• Management (former SONN): Management roles and responsibilities would be redefined under HSI's corporate structure.

Next Steps

• Integration of Sonnet BioTherapeutics Holdings, Inc. into Hyperliquid Strategies Inc.
• Potential future disclosures from Hyperliquid Strategies Inc. regarding the acquired assets or CVR performance.

Key Dates

Keywords

Sonnet BioTherapeutics Holdings Inc, SONN, Hyperliquid Strategies Inc, HSI, Merger, Business Combination Agreement, Form 4, Insider Transaction, Restricted Stock Units, CVR, Reverse Stock Split, John K. Cini